Robert Blum, CEO of Cytokinetics, discusses the company's aficamten, cardiac myosin inhibitor, and potential treatments for cardiovascular diseases. They cover aficamten's administration, path to commercialization, impact on patients, and future applications. The conversation also explores CK-136 and omecamtiv mecarbil as innovative pharmacological approaches in cardiac muscle activation for heart health.